Omnicell (NASDAQ:OMCL) Stock Rating Reaffirmed by Benchmark

Omnicell (NASDAQ:OMCL)‘s stock had its “buy” rating reiterated by Benchmark in a note issued to investors on Tuesday, Benzinga reports. They currently have a $38.00 price target on the stock. Benchmark’s price target would suggest a potential upside of 40.48% from the stock’s current price.

A number of other research firms also recently commented on OMCL. Barclays began coverage on Omnicell in a report on Wednesday, January 3rd. They issued an “underweight” rating and a $33.00 price objective for the company. Wells Fargo & Company decreased their price target on shares of Omnicell from $28.00 to $26.00 and set an “equal weight” rating for the company in a research note on Friday, February 9th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $42.20.

Omnicell Price Performance

Shares of OMCL stock traded down $0.35 during trading on Tuesday, hitting $27.05. The company had a trading volume of 37,545 shares, compared to its average volume of 531,162. The stock’s 50-day moving average is $27.64 and its two-hundred day moving average is $32.04. Omnicell has a 52 week low of $25.69 and a 52 week high of $77.14. The stock has a market capitalization of $1.24 billion, a price-to-earnings ratio of -60.07 and a beta of 0.76. The company has a quick ratio of 2.22, a current ratio of 2.52 and a debt-to-equity ratio of 0.48.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, February 8th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.22. The firm had revenue of $258.85 million during the quarter, compared to the consensus estimate of $256.00 million. Omnicell had a negative net margin of 1.78% and a positive return on equity of 3.43%. As a group, analysts predict that Omnicell will post 0.09 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Arkadios Wealth Advisors boosted its holdings in Omnicell by 30.6% during the first quarter. Arkadios Wealth Advisors now owns 30,010 shares of the company’s stock valued at $877,000 after acquiring an additional 7,025 shares during the period. Principal Financial Group Inc. increased its holdings in shares of Omnicell by 3.9% during the first quarter. Principal Financial Group Inc. now owns 264,083 shares of the company’s stock valued at $7,719,000 after acquiring an additional 9,944 shares in the last quarter. Benjamin Edwards Inc. increased its position in shares of Omnicell by 36.4% during the 1st quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock valued at $95,000 after purchasing an additional 868 shares during the last quarter. Horrell Capital Management Inc. increased its holdings in Omnicell by 82.0% in the 1st quarter. Horrell Capital Management Inc. now owns 91,000 shares of the company’s stock worth $2,660,000 after buying an additional 41,000 shares during the period. Finally, Assenagon Asset Management S.A. raised its holdings in shares of Omnicell by 2.2% during the first quarter. Assenagon Asset Management S.A. now owns 371,835 shares of the company’s stock worth $10,869,000 after purchasing an additional 8,096 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.